Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Acta Cardiol ; 68(2): 189-91, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23705562

RESUMO

We present a case of severe haemolysis and acute renal failure 5 weeks following mitral valve repair of mitral valve prolapse. Intravascular haemolysis in this patient was caused by fragmentation of a mitral regurgitant jet due to residual prolapse and partial dehiscence of the mitral valve repair ring. Urgent redo mitral valve repair was successful in resolving the mitral regurgitation and haemolysis, but renal function parameters could not be restored to normal values.


Assuntos
Injúria Renal Aguda/etiologia , Hemólise , Prolapso da Valva Mitral/cirurgia , Ecocardiografia Doppler em Cores , Ecocardiografia Transesofagiana , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Insuficiência da Valva Mitral/diagnóstico por imagem , Insuficiência da Valva Mitral/etiologia , Prolapso da Valva Mitral/complicações , Reoperação
2.
Eur J Heart Fail ; 24(9): 1601-1610, 2022 09.
Artigo em Inglês | MEDLINE | ID: mdl-35733283

RESUMO

AIMS: To describe the baseline characteristics of participants in the Acetazolamide in Decompensated Heart Failure with Volume Overload (ADVOR) trial and compare these with other contemporary diuretic trials in acute heart failure (AHF). METHODS AND RESULTS: ADVOR recruited 519 patients with AHF, clinically evident volume overload, elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) and maintenance loop diuretic therapy prior to admission. All participants received standardized loop diuretics and were randomized towards once daily intravenous acetazolamide (500 mg) versus placebo, stratified according to study centre and left ventricular ejection fraction (LVEF) (≤40% vs. >40%). The primary endpoint was successful decongestion assessed by a dedicated score indicating no more than trace oedema and no other signs of congestion after three consecutive days of treatment without need for escalating treatment. Mean age was 78 years, 63% were men, mean LVEF was 43%, and median NT-proBNP 6173 pg/ml. The median clinical congestion score was 4 with an EuroQol-5 dimensions health utility index of 0.6. Patients with LVEF ≤40% were more often male, had more ischaemic heart disease, higher levels of NT-proBNP and less atrial fibrillation. Compared with diuretic trials in AHF, patients enrolled in ADVOR were considerably older with higher NT-proBNP levels, reflecting the real-world clinical situation. CONCLUSION: ADVOR is the largest randomized diuretic trial in AHF, investigating acetazolamide to improve decongestion on top of standardized loop diuretics. The elderly enrolled population with poor quality of life provides a good representation of the real-world AHF population. The pragmatic design will provide novel insights in the diuretic treatment of patients with AHF.


Assuntos
Insuficiência Cardíaca , Desequilíbrio Hidroeletrolítico , Acetazolamida/uso terapêutico , Idoso , Diuréticos/uso terapêutico , Feminino , Humanos , Masculino , Peptídeo Natriurético Encefálico/uso terapêutico , Fragmentos de Peptídeos/uso terapêutico , Qualidade de Vida , Inibidores de Simportadores de Cloreto de Sódio e Potássio/uso terapêutico , Volume Sistólico , Função Ventricular Esquerda
5.
Eur J Emerg Med ; 24(4): 249-254, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-26657212

RESUMO

BACKGROUND: In out-of-hospital cardiac arrest (OHCA), neurological outcome is determined by the severity of neurological injury, early percutaneous coronary intervention, and application of neuroprotective temperature management. As this is a very time-intensive and manpower-intensive protocol, we hypothesized that there would be a difference in outcome between OHCA patients admitted during and out of office hours. METHODS: We prospectively collected demographic data of OHCA patients in two hospitals. All patients included were treated at 33°C for 24 h, followed by a rewarming phase until 36.6°C. During office hours were defined as arriving between 8:00 a.m. and 5:00 p.m. on weekdays. Neurological outcome at 180 days was assessed following the Cerebral Performance Category scale. RESULTS: Forty-seven (31%) patients were admitted during office hours and 105 (69%) out of office hours (P=0.199). Patients admitted during office hours were significantly older, respectively, 66±14 and 59±15 years (P=0.014). There was no significant difference between both groups in the number of patients who underwent coronary angiography, door to angiography time, and number of affected vessels. The median time spent in the target range of PaO2, PaCO2, and lactate was also not significantly different. We found no significant difference in survival until 180 days between both groups (P=0.599), even after adjustment for age (95% confidence interval: 0.44-1.90, hazard ratio: 0.912). CONCLUSION: Survival until 180 days between OHCA patients admitted during office hours or out of office hours was not significantly different in two hospitals with a fixed protocol for neuroprotection and 24/7 streamlined access to coronary angiography.


Assuntos
Plantão Médico/estatística & dados numéricos , Hospitalização/estatística & dados numéricos , Parada Cardíaca Extra-Hospitalar/terapia , Idoso , Angiografia Coronária/estatística & dados numéricos , Feminino , Humanos , Hipotermia Induzida/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Parada Cardíaca Extra-Hospitalar/diagnóstico , Parada Cardíaca Extra-Hospitalar/diagnóstico por imagem , Parada Cardíaca Extra-Hospitalar/mortalidade , Estudos Prospectivos , Fatores de Tempo , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA